Dr. Catriona H. Jamieson, MD, PhD

Dr. Jamieson practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Jamieson's NPI, 1841223617, was assigned on July 7, 2006. Dr. Jamieson graduated from University of British Columbia in 1995. Dr. Jamieson holds California license A67419.

Dr. Jamieson's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Jamieson's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Jamieson is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jamieson practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Jamieson's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Jamieson is board certified in hematology by the American Board of Internal Medicine. Dr. Jamieson is licensed in California.

Dmand AI lists chronic leukemia, lung cancer and lymphoma among the conditions Dr. Jamieson treats.

CMS data shows 185 Medicare services from Dr. Jamieson across 1 procedure code in 2024, all of them office visits, for 72 Medicare patients. Medicare paid $13,638 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 72 Medicare patients who saw Dr. Jamieson in 2024. The largest group is 75 to 84, with 30 patients. 74% of them have high cholesterol, and 64% have high blood pressure. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jamieson's median patient age at 65, with 53% women.

In 2024, Dr. Jamieson wrote 536 Medicare Part D claims for 60 patients. 23% of them were for generic drugs. CMS names the drug for 501 of them, across 8 drugs with 11 or more claims each, at $6,145,384 in total drug cost. In 2023, CMS named 473 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Jamieson for performance year 2024, reported as part of a group. Dr. Jamieson accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 97 papers to Dr. Jamieson, published from 2003 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive and Hematopoietic Stem Cells. Dr. Jamieson has published most often in Cell Stem Cell. Dr. Jamieson's most frequent co-authors are Ruben Anthony Mesa, MD, Jason Gotlib, MD, MS and Thomas J. Kipps, MD.

Dmand AI links Dr. Jamieson to 4 clinical trials, 2 of them phase 1/2 studies. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive and Lymphoma, B-Cell, Marginal Zone.

CMS Open Payments shows 30 general payments to Dr. Jamieson from 7 drug and device companies from 2016 to 2023. Speaker and faculty fees make up the largest share, 86% of the total. Pfizer Inc. paid the most, $22,780. It also lists 1 research payment totaling $3,200 in 2020.

Dmand AI lists 4 awards for Dr. Jamieson, most recently CMS Stage 1 EHR in 2013.

Dr. Jamieson graduated from University of British Columbia in 1995.

Dr. Jamieson is in network with 14 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.